Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Onconetix, Inc. (ONCO : NSDQ)

• Company Description    Onconetix Inc. is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. Onconetix Inc., formerly known as Blue Water Biotech Inc., is based in CINCINNATI. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $2.30 Daily Weekly Monthly 20 Day Moving Average: 35,971 shares Shares Outstanding: 1.56 (millions) Market Capitalization: $3.59 (millions) Beta: 3.42 52 Week High: $79.05 52 Week Low: $2.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.74% -6.98% 12 Week -23.33% -25.53% Year To Date -95.69% -96.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 East Fifth Street Suite 1900 - CINCINNATI,OH 45202 USA ph: 513-620-4101 fax: - investors@onconetix.com https://onconetix.gcs-web.com

• General Corporate Information    Officers Karina Fedasz - Chief Executive Officer and Interim Chief Financia Andrew Oakley - Chairman Thomas Meier - Director Timothy Ramdeen - Director Ajit Singh - Director Peer Information Onconetix, Inc. (CORR.) Onconetix, Inc. (RSPI) Onconetix, Inc. (CGXP) Onconetix, Inc. (BGEN) Onconetix, Inc. (GTBP) Onconetix, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68237Q203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 06/01/26 Share - Related Items Shares Outstanding: 1.56 Most Recent Split Date: 6.00 (0.01:1) Beta: 3.42 Market Capitalization: $3.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/01/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.06 Price/Cash Flow: - Price / Sales: 2.93 EPS Growth vs. Year Ago Period: 96.71% vs. Previous Quarter: -54.32% Sales Growth vs. Year Ago Period: -25.31% vs. Previous Quarter: 184.11% ROE 09/30/25 - -632.63 06/30/25 - -192.74 03/31/25 - -514.04 ROA 09/30/25 - -160.97 06/30/25 - -89.55 03/31/25 - -75.82 Current Ratio 09/30/25 - 0.08 06/30/25 - 0.07 03/31/25 - 0.17 Quick Ratio 09/30/25 - 0.07 06/30/25 - 0.06 03/31/25 - 0.16 Operating Margin 09/30/25 - -2,817.14 06/30/25 - -2,157.76 03/31/25 - -1,656.75 Net Margin 09/30/25 - -4,011.43 06/30/25 - -3,327.03 03/31/25 - -2,913.71 Pre-Tax Margin 09/30/25 - -4,086.37 06/30/25 - -3,400.45 03/31/25 - -2,961.68 Book Value 09/30/25 - 2.17 06/30/25 - 5.86 03/31/25 - 9.05 Inventory Turnover 09/30/25 - 1.37 06/30/25 - 3.60 03/31/25 - 8.08 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©